Metabolomics application in maternal-fetal medicine by V. Fanos et al.
Hindawi Publishing Corporation
BioMed Research International
Volume 2013, Article ID 720514, 9 pages
http://dx.doi.org/10.1155/2013/720514
Review Article
Metabolomics Application in Maternal-Fetal Medicine
Vassilios Fanos,1 Luigi Atzori,2 Karina Makarenko,3
Gian Benedetto Melis,4 and Enrico Ferrazzi3
1 NICU, Puericulture Institute and Neonatal Section, AOU and University of Cagliari, 09124 Cagliari, Italy
2 Department of Biomedical Science, University of Cagliari, 09124 Cagliari, Italy
3 Department of Woman, Mother and Neonate, Buzzi Hospital, Biomedical and Clinical Sciences School of Medicine,
University of Milan, 20122 Milan, Italy
4Department of Obstetrics and Gynecology and Human Reproduction Physiopathology, University of Cagliari,
09124 Cagliari, Italy
Correspondence should be addressed to Enrico Ferrazzi; enrico.ferrazzi@unimi.it
Received 19 April 2013; Revised 10 May 2013; Accepted 13 May 2013
Academic Editor: Kaei Nasu
Copyright © 2013 Vassilios Fanos et al.This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Metabolomics in maternal-fetal medicine is still an “embryonic” science. However, there is already an increasing interest in
metabolome of normal and complicated pregnancies, and neonatal outcomes. Tissues used for metabolomics interrogations of
pregnant women, fetuses and newborns are amniotic fluid, blood, plasma, cord blood, placenta, urine, and vaginal secretions. All
published papers highlight the strong correlation between biomarkers found in these tissues and fetal malformations, preterm
delivery, premature rupture of membranes, gestational diabetes mellitus, preeclampsia, neonatal asphyxia, and hypoxic-ischemic
encephalopathy. The aim of this review is to summarize and comment on original data available in relevant published works in
order to emphasize the clinical potential of metabolomics in obstetrics in the immediate future.
1. Introduction
Metabolomics (or metabonomics) is the youngest and pos-
sibly the most promising among “omics technologies.” It
represents a holistic approach to the metabolites that con-
stitute a cell, tissue, or organism [1]. It is able to provide a
phenotypic fingerprinting of a cell, tissue, or organism by
virtue of its ability to measure multiple metabolites directly
from complex biological systems. Any molecule less than
1 kDa in mass can be sorted out by metabolomics technology
as a single final product of active/inactive genes in a given
condition (genome), its activation (mRNA transcriptome),
the setup of enzymatic machineries (proteome), and their
actual biological processes.
Metabolomic studies in pregnancy are not a novel con-
cept. Since the 1960s, the role of specific single metabolites
in the dynamic interactions among fetus, placenta, and
pregnant woman had been reported in various studies [2–6].
However, metabolomics in pregnancy, under present high-
through-output technologies, is still an “embryonic” science:
in 2009, the first review on this topic had been published
based on limited data [1], the state of art situation has not
changed much since then except for the fact that recent
studies prove again and again the immense possibilities of
this technology in the complex field of pregnancy where two
partner organisms are interacting formutual benefit [5, 7–11].
2. The Metabolomic Approach
Themetabolomic approach consists of two sequential phases.
The analytical phase is designed to profile all low molecular
weight metabolites in a given biological specimen to generate
an all-inclusive spectrum. Possible sources of biological
tissues that can be exploited in pregnancy are both from the
mother (plasma, urine, vaginal fluids, milk), the fetus (amni-
otic fluid, umbilical cord blood), and the newborn (plasma,
urine, placenta, saliva, other fluids). Different technologies
might be generally adopted: nuclear magnetic resonance
(NMR) spectroscopy, gas chromatography-mass spectrome-
try (GC-MS), and liquid chromatography-mass spectrometry
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(LC-MS). The phase of data analysis and interpretation
requires highly complex data mining software and an ample
database ofmetabolites to describe the nodes and networking
of metabolic pathways [7, 8, 12–27]. In a recent paper, we
described in detail these phases in studies performed in
pregnant women and neonates [25].
3. Metabolomics in Plasma of
Pregnant Women
To the best of our knowledge, metabolomic analysis per-
formed on plasma of pregnant women had been reported
in eight studies [2, 7, 8, 18, 26–29] addressing different
pregnancy complications. Plasma samples were analyzed
with NMR or LC-MS. Main results of these studies are
reported in Table 1.
Lower plasma betaine and trimethylamine-N-oxide con-
centrations [18] were observed in maternal plasma in case of
fetal malformation. Additional different significant findings
were reported for amino acids involved in gluconeogenesis,
for cis-aconitate, acetone, 3-hydroxybutyrric, and hypox-
anthine. These data suggest that the malformed fetuses
demand enhanced gluconeogenesis and tricarboxylic acids
cycle (Krebs Cycle), possibly due to hypoxic metabolism.
Significant differences were observed also between normal
pregnancies and cases which would later develop gesta-
tional diabetes. Changes in 3-hydroxyisovalerate and 2-
hydroxyisobutirrate were observed, suggesting early changes
in biotin status and altered aminoacid and/or gutmetabolism.
Preeclampsia (PE) had been a major focus in metabolomics
technologies applied to maternal-fetal medicine. Both Kenny
et al. [26] and Odibo et al. [27] focused their studies on
predicting preeclampsia. Kenny’s work was mainly focused
on late preeclampsia of maternogenic origin, as we can
argue from the limited prevalence of small for gestational
age (SGA) newborns in his cohort, and early and late PE
were not objects of a different analysis. Odibo in a slightly
smaller sample observed a lower detection rate for early
onset preeclampsia only. Unfortunately, the lack of consis-
tent classification of hypertensive disorder in pregnancy as
regards the relationship between early onset preeclampsia
and late onset preeclampsia and placental vascular damage
[17] might impact adversely the correlations observed in the
metabolome in cases with and cases without early placental
vascular damage and fetal growth restriction (FGR) [9].
Very recently Bahado-Singh et al. [7, 8] published 2
papers focusing on early onset and late onset preeclampsia,
selected by the calendar based definition of early and late
preeclampsia and by evidence of placental damage in early
onset preeclampsia. NMR-based metabolomic analysis was
performed onfirst-trimestermaternal serumat 11–13weeks of
gestation to assess the possible prediction of late preeclamp-
sia. A parsimonious genetic computingmodel proved yielded
60% sensitivity at 96.6% specificity for late preeclampsia
prediction. A comparisonwith database of the previous study
on early onset preeclampsia proved a strong separation of
late-versus early-onset preeclampsia groups. Twometabolites
based on the VIP plot were notable for their differences
between preeclamptic and normal pregnant women: glycerol
and carnitine. Glycerol and carnitine are both important
for lipid metabolism and mitochondrial energy productions
based on lipids. More significantly carnitine inhibits oxida-
tive stress. All these metabolic pathways are overexpressed
in metabolic syndrome and its acute expression in late
preeclampsia.
4. Metabolomics in Urine of
Pregnant Women and Neonates
Table 2 reports the relevant methodology, results, and con-
clusions of five studies investigation metabolomics findings
in urine of pregnant women and neonates [30–34]. In
pregnant women with fetuses affected by somatic abnormal-
ities metabolomics findings confirmed enhanced plasmatic
concentration of glucogenic amino acids aswell as an increase
in hypoxanthine concentration and tricarboxylic acid cycle
suggesting ATP degradation and fetal stress.
A possible role of methionine, phenylalanine, histidine,
andhexose (possibly glucose) changes in pretermdelivery has
been suggested.
Inositol phosphoglycan P type (P-IPG) has been linked
to insulin resistance, thus making its raise an important
marker in Gestational Diabetes Mellitus (GDM) evaluation,
fetal growth alterations, and preeclampsia prediction.
Generic markers of prenatal disorders, such as preeclamp-
sia, hypoxia, chromosomal disorders, or prediagnostic GDM,
are N-methyl-2-pyridone-5-carboxamide and N-methylnico
tinamide (products of abnormal nucleotide meta bolism)
most likely increasing due to the effects of stress.
In a recent paper by Diaz and coworkers [18], maternal
plasma and urine were collected and analysed with NMR.
Metabolic alterations observed in maternal biofluids in preg-
nancies with fetal malformations, chromosomal disorders,
GDM, PPROM, and preterm delivery suggest potential use
of metabolomics in identifying women at risk of prenatal and
maternal pregnancy-related disorders. The study by Dess`ı
and coworkers on neonatal urine demonstrated the potential
of metabolomics in identifying FGR foetuses and contribut-
ing to their clinical management [34] with metabolomics
analysis of neonatal urine being another promising field for
further investigation [19, 20, 35]. In a preliminary study by
our group, a metabolomic approach on maternal urine was
used for the diagnosis of labor, suggesting that it is possible
to anticipate the timing of delivery [36].
5. Metabolomics in Amniotic Fluid
Metabolomic analysis of amniotic fluid, mainly determined
with NMR and MS (ULPC and LC), has been reported by
several studies addressing different pregnancy complications
[3, 30, 37–41]. Main results of these studies are presented in
Table 3.
Amniotic fluid biomarkers seemed to have the best
predictive value for malformed fetuses; in this case, lower
glucose and higher free lactate levels indicate that energy
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Table 1: Methodology, findings, and main conclusions derived from metabolomics studies on maternal plasma.
Population Gestational ageat examination
Metabolomic
analysis
Main differences in
abnormal pregnancies
Significance/take-home
messages Reference Author, year
20 normal
pregnancies Matched
27 fetal
malformations At diagnosis
Gluconeogenetic
aminoacids, cis-aconitate,
acetone, 3-hydroxibutirric,
hypoxanthine
Pregnant women with
malformed fetus showed
enhanced glucogenesis and
tricarboxylic acids cycle
23 chromosomal
disorders At diagnosis NMR [18]
Diaz et al.,
2011
14 prediagnostic
GDM
Before positive
OGTT
3-Hydroxyisovalerate,
2-hydroxyisobutirrate
Pregnant women who later
develop GDM showed early
changes in biotin status and
altered aminoacid and/or
gut metabolism
18 pPROM At diagnosis No alterations
11 normotensive
pregnancies
versus 11
preeclamptic
pregnancies
n.r. NMR Hystidine, tyrosine,phenylalanine
Diagnosis of preeclampsia
was possible by
metabolomics
[28] Turner et al.,2008
60 cases of PE
versus matched
controls
15 ± 1 weeks UPLC-MS 40 metabolites (detectionrate 71%, 5% false positive)
Metabolomics might
predict preeclampsia, early
and late PE not analysed
separately
[26] Kenny et al.,2010
41 cases of PE
versus controls First trimester LS/MS
40 acylcarnitine species
and 32 aminoacids
(AUC-ROC = 0.85)
Metabolomics might
predict early onset PE [27]
Odibo et al.,
2011
30 cases of early
PE versus 60
controls
First trimester NMR
Citrate, glycerol,
hydroxyisovalerate, and
methionine and uterine
Doppler abnormal PI
(detection rate of 82.6%, at
an FPR of 1.6%)
Metabolomics might
predict early onset PE [7]
Bahado-
Singh et al.,
2012
30 cases of late
PE versus 119
controls
First trimester NMR 17 metabolites Metabolomics mightpredict late onset PE [8]
Bahado-
Singh et al.,
2013
Pregnant
women who
subsequently
delivered an
SGA baby
First trimester UPLC-MS 19 metabolites (OR = 44;AUC-ROC = 0.90)
Metabolomics might
predict SGA [29]
Horgan et al.,
2011
GDM: gestational diabetes mellitus; pPROM: preterm premature rupture of membranes; OGTT: oral glucose tolerance test; NMR: nuclear magnetic resonance
spectroscopy; PE: preeclampsia; UPLC-MS: ultra performance liquid chromatography-mass spectrometry; LS/MS: liquid chromatography-mass spectrometry;
SGA: small for gestational age.
production is being conducted preferentially through gly-
colysis under anaerobic (hypoxic) conditions and a reduced
use of mitochondrial respiratory chain pathway (reflected by
succinate increase). Due to hypoxia less glucose is available
to other tissues and in order to replenish the glucose level
an augmented glucose production via gluconeogenesis is
observed (with a resulting decrease in gluconeogenic amino
acids levels).
Higher glutamine level, glutamine/glutamate ratios,
increase in glycoprotein P1, and lower urea level reflect
kidney disorders/underdevelopment. Changes in glycine,
serine, 𝛼 oxoisovalerate, leucine, and ascorbate suggest a
disturbance in amino acid biosynthesis. Amniotic fluid
changes described above are characteristic for the whole
group of malformations indicating changes in glycolysis,
gluconeogenesis, and kidney underdevelopment.
Data regarding GDM (increase of glucose level consistent
with previously reported insulin increase; slight reduction
of several amino acids, creatinine, acetate, formate, glyc-
erophosphocholine) suggest changes in amino acids biosyn-
thesis, higher demand for protein, and changes in lipid
metabolism, and renal function.
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Table 2: Methodology, findings, and main conclusions derived from metabolomics studies on maternal and neonatal urine.
Population study Gestational ageat examination
Metabolomic
analysis Main results
Significance/take-home
messages Reference Author, year
48 GDM cases versus
23 controls
Third
trimester MS
Increased urinary
excretion of P-IPG,
positive correlation with
blood glucose
Metabolomic
identification of P-IPG is
a potential marker of
insulin resistance, may
predict fetal growth
alterations in GDM
patients
[33] Scioscia et al.,2007
9 PE cases versus 84
controls
First
trimester
Elisa-based
assay
Rapid raise of P-IPG
(sensitivity and
specificity of 88.9% and
62.7%, resp.)
Metabolomics by
multiple assessment of
samples might predict
preeclampsia
[32] Paine et al.,2010
3083 pregnancies
positive to the
screening of
Smith-Lemli-Opitz
syndrome
Second
trimester GC/MS
16𝛼-OH-DHEA, urine
total estriol. Fetal steroid
sulfatase deficiency 98%
detection rate, 95% CI
92–99
Metabolomics analysis of
Maternal urine steroids
is effective in detecting
STSD. Possible use for
diagnosing ADHD and
CGDS (common in
association with STSD)
[31] Marcos et al.,2009
75 pregnancies (13
healthy)
Potential of the tandem
use of MS and NMR for
metabolomics studies of
urine and amniotic fluid
in pregnant women
13 fetal malformations Hippurate, amino acids
20 predisposition to
GDM
Second
trimester
UPLC-MS
NMR No relevant changes [30]
Grac¸a et al.,
2012
6 preterm delivery
Methionine,
phenylalanine, hystidine,
hexose (possibly
glucose)
26 preterm FGR
versus 30 preterm
appropriate for
gestational age
Neonates 1H NMR Myoinositol, sarcosine,creatine, and creatinine
Metabolomics might
identify FGR and
contribute to the clinical
management of FGR
neonates
[34] Dess`ı et al.,2011
GDM: gestational diabetes mellitus; MS: mass spectrometry; P-IPG: inositol phosphoglycan P type; PE: preeclampsia; GC/MS: gas chromatography-mass
spectrometry; STSD: steroid sulfatase deficiency; ADHD: attention deficit-hyperactivity disorder; CGDS: contiguous gene deletion syndrome; UPLC-MS:
ultra performance liquid chromatography-mass spectrometry; NMR: nuclear magnetic resonance spectroscopy; 1HNMR: proton nuclear magnetic resonance
spectroscopy; FGR: fetal growth restriction.
A derangement of amino acid metabolism due to obser-
ved increase in succinic acid and glutamine concentration
and significantly lower concentrations of creatine and crea-
tinine has been suggested for the spina bifida cases analyzed
with metabolomics techniques.
The changes observed in the amniotic fluid related to
preterm delivery include increase of allantoine (a marker of
oxidative stress) and a decrease of myoinositol that promotes
fetal lung maturation.
Two recent cross-sectional metabolomics studies report-
ed the importance of the amniotic fluid metabolic signature
for preterm labor (PTL)with or without intra-amniotic infec-
tion or inflammation (IAI) [3, 41]. Amniotic fluid biomarkers
were able to discriminate 3 groups based on the pregnancy
outcome [41]: (1) patients with PTLwho delivered at term, (2)
patients with PTLwithout IAI who delivered preterm, and (3)
patients PTL with IAI who delivered preterm (characterized
by an increase in amino acid metabolites). A reduction
of carbohydrates in the amniotic fluid was associated with
preterm delivery (with or without IAI). Methyladenine and
diaminopimelic acid, components of bacterial processes
and bacterial wall, respectively, were the most significant
biomarkers in this clinical condition.
These studies show the potential of human amniotic fluid
metabolome analysis as the basis for the development of rapid
tests to differentiate between patients at risk of impending
preterm birth (with or without infection/inflammation) and
patients who will deliver at term.
6. Metabolomics in Placenta
Metabolomic analysis of placenta has been reported in several
scientific papers [4–6, 10, 11]. The results of these studies are
presented in Table 4.
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Table 4: Methodology, findings, and main conclusions derived from metabolomics studies on placenta tissues.
Population study Material Metabolomicanalysis Main results
Significance/take-
home
messages
Reference Author, year
9 SGA cases
versus 8 controls
Placenta
villous
explants
UPLC-MS
574 metabolites were significantly
different between SGA and
controls; 49% of metabolites of
interest were the same for SGA
explant cultured under hypoxic
conditions and controls cultured
under normoxic conditions
Changes in phospholipids,
essential amino acids (tryptophan,
methionine, and phenylalanine)
concentrations
Metabolomics might
predict SGA [11]
Horgan et al.,
2010
11 uncomplicated
term pregnancies
Placenta
villous
explants
GC-MS
Cultured in 1%, 6%, and 20%
oxygen. Differences in
2-deoxyribose, threitol/erythritol,
hexadecanoic acid
Metabolomics can be
applied to placenta
studies and could help
in detecting hypoxia
[10] Heazell et al.,2008
6 cases of
preeclampsia
versus 6 controls
Villous
trophoblast UPLC-MS
47 metabolites in
preeclampsia-derived media
cultured under normoxic
conditions showed similarities to
that of uncomplicated pregnancies
cultured under hypoxic
conditions. Alterations in
glutamate and glutamine,
leukotrienes and prostaglandins,
kynurenine metabolism
Metabolomics might
predict preeclampsia
of placental origin
developed due to
hypoxia
[4] Dunn et al.,2009
8 cases of
labor/Cesarean
section at 3100m
versus 8 controls
with
labor/Cesarean
section delivery at
sea level
Placenta
1H NMR,
31P NMR
At sea level: metabolic markers of
oxidative stress, increased
glycolysis, elevated cholesterol,
and free amino acids. At 3100 m:
metabolic profiles with adaptation
to chronic hypoxia, decreased
reliance on anaerobic glycolysis;
presence of concentrations of
stored energy potential
(phosphocreatine), antioxidants
(taurine, inositol), and low free
amino acid concentrations
Metabolomics might
help identify subjects
under hypoxic stress
(chronic hypoxic
preconditioning state
versus acute
ischemic/hypoxic
insult)
[6]
Tissot van
Patot et al.,
2010
SGA: small for gestational age; UPLC-MS: ultra performance liquid chromatography-mass spectrometry; GC-MS: gas chromatography-mass SPECTROME-
TRY; 1H NMR: proton nuclear magnetic resonance spectroscopy; 31P NMR: phosphorus nuclear magnetic resonance spectroscopy.
Dunn and coworkers [4] studied the metabolomic respo-
nse of the normal and preeclamptic placental tissue to differ-
ent oxygen levels. Placental tissue from uncomplicated preg-
nancies cultured in 1% oxygen (hypoxia) showed metabolic
similarities to explants from late-onset preeclampsia preg-
nancies cultured at 6% oxygen (normoxia) thus suggesting
an important role of hypoxia in preeclampsia development.
Specific metabolic alterations included lipids, glutamate, glu-
tamine, and metabolites related to tryptophan, leukotrienes,
and prostaglandins.Thesemetabolic changes were confirmed
by Horgan and coworkers [11] that in a similar study
compared placental features seen in small for gestational
age (SGA) cases versus controls. Placental tissue from both
groups was cultured in 1%, 6%, and 20% oxygen. There
was a significant difference in more than 500 metabolites
between SGA and normal pregnancies at different oxygen
tensions, while 49% of metabolites of interest were similar
under normoxic conditions suggesting in vivo adjustment
to hypoxia by SGA fetus, with a further consideration that
normal oxygen level could worsen metabolic dysfunction of
the placenta of a SGA fetus. This study reinforces the role
of hypoxia and oxidative stress in preeclampsia and SGA.
The role of chronic hypoxia was also studied by Tissot van
Patot and colleagues [6], who reported the placentas at 3100m
sea level, naturally present higher concentrations of stored
energy potential, antioxidants, and lower free amino acid
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concentrations, with better resistance to hypoxia and less
evidentmetabolic stress response, and their results suggesting
adaptation to chronic hypoxia in placenta at high altitude.
7. Metabolomics in Vaginal Secretion
Apilotmass spectrometrymetabolomic study of womenwho
had a spontaneous preterm birth compared to controls was
conducted using the uterine cervical length as a selective
factor. Noninvasive collection of cervicovaginal secretions
from 15 women (women with a short cervix who had a
spontaneous preterm birth compared to a control cohort
with a short cervix and with a long cervix) was performed,
and 17 markers of interest were identified. This particular
metabolomic approach may help in the management of
women at highrisk for spontaneous preterm birth [16].
8. Metabolomics in Cord Blood
Metabolomic analysis of cord blood has been carried out
on samples collected from low birth weight (LBW) new-
borns, very low birth weight (VLBW) newborns, newborns
diagnosed with FGR, SGA during pregnancy, newborns with
asphyxia, and hypoxic ischemic encephalopathy. The results
were reported in five studies [29, 42–45]. In the paper by
Ivorra and coworkers [42] seven metabolites were able to
discriminate a specific LBW metabolome, with a significant
positive correlation between birth weight and proline, glu-
tamine, free choline and negative correlation with citrulline
and phenylalanine levels. These findings demonstrate the
differences in the anabolic rate of the LBWnewborns and the
possible consequences that these metabolites’ modifications
can exercise on the newborn’s health (e.g., maternal choline
and its metabolite betaine supply modifying fetal histone
and DNA methylation). It is also noteworthy that these
changes were observed in the newborns only and not in their
mothers, suggesting possible involvement of impaired pla-
cental transport of amino acids.Metabolic findings described
above reveal the potential of metabolomics in identifying
the population at risk. Tea and coworkers [43], analysing
the cord blood from VLBW infants, demonstrated that a
number of metabolites (glucose, acetate, lipids, pyruvate,
glutamine, valine, threonine,) vary depending on gestational
age at delivery. In the study by Favretto and coworkers
[44], FGR presented changes in 22 metabolites with the
most evident modifications in the following aminoacids
composition: phenylalanine, tryptophan, and glutamate with
91–100% sensitivity and 85–89% specificity. Cut-off values
for phenylalanine and tryptophan were identified. This study
demonstrates that metabolomics is a promising tool for
identification of FGR fetuses.
Horgan and coworkers [29] observed that 19 metabolites
(including sphingolipids, phospholipids, carnitines) differen-
tiate SGA fromcontrols, providing a base for a valid screening
test for presymptomatic SGA or FGR. Early identification
of cases at risk would help to develop adequate clinical
management of patients to avoid serious complications.
Another study that confirms one more time the importance
of metabolomic analysis for the future of the medicine, in
this case producing a robust predictive model for detecting
encephalopathy in the newborns at 24 hours of life, in order
to be able to provide the best timely treatment for the young
patient is that of Walsh and coworkers [45]. This study
found 29 metabolites among amino acids, acylcarnitines and
glycerophospholipids to be significantly different in neonates
with hypoxic ischaemic encephalopathy (HIE) versus con-
trols or asphyxia versus controls groups, with 5 metabolites
(2 acylcarnitines, 1 glycerophospholipid and 2 aminoacids)
clearly delineating the severity of asphyxia and the degree of
HIE.
All these data suggest that metabolomics is a noninvasive
promising novel way of investigation, with the goal of
understanding better the pathogenesis of different diseases,
developing screening tests and helping in clinical manage-
ment of the patients.
9. Conclusions
Metabolomics appears to be one of the most promising novel
tools in obstetrics, among other important “omics”. A recently
published paper was entitled “Can biofluids metabolic pro-
filing help us to improve health care during pregnancy?”
[46]. The answer is “probably yes” if all these preliminary
data on the potential usefulness of biofluids metabolomics
in perinatal disorders are further investigated, single diseases
are targeted and results are confirmed.
Through the metabolome we can observe the enormous
and complex interactions between mother, placenta, and
fetus. This high throughput technology might allow us to
identify key role nodes for prediction, diagnosis, and mon-
itoring of different obstetrics conditions.
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